Oxathiazolones selectively inhibit the human immunoproteasome over the constitutive proteasome

ACS Medicinal Chemistry Letters

Volumn 5, Issue 4, 2014, Pages 405-410

  Fan, Hao ^a   Angelo, Nicholas G ^a   Warren, J David ^a   Nathan, Carl F ^a   Lin, Gang ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

autoimmune disease; constitutive proteasome; Immunoproteasome; selective inhibitor

Indexed keywords

IMMUNOPROTEASOME BETA5I; PROTEASOME; PROTEASOME INHIBITOR; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL PERMEABILIZATION; CONFORMATIONAL TRANSITION; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL;

EID: 84898052676     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400531d     Document Type: Article

References (24)

1. Bedford, L.; Lowe, J.; Dick, L. R.; Mayer, R. J.; Brownell, J. E. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets Nat. Rev. Drug Discovery 2011, 10 (1) 29-46
2. Nalepa, G.; Rolfe, M.; Harper, J. W. Drug discovery in the ubiquitin-proteasome system Nat. Rev. Drug Discovery 2006, 5 (7) 596-613
3. Baumeister, W.; Walz, J.; Zuhl, F.; Seemuller, E. The proteasome: paradigm of a self-compartmentalizing protease Cell 1998, 92 (3) 367-380
4. Adams, J. The proteasome: a suitable antineoplastic target Nat. Rev. Cancer 2004, 4 (5) 349-360
5. Muchamuel, T.; Basler, M.; Aujay, M. A.; Suzuki, E.; Kalim, K. W.; Lauer, C.; Sylvain, C.; Ring, E. R.; Shields, J.; Jiang, J.; Shwonek, P.; Parlati, F.; Demo, S. D.; Bennett, M. K.; Kirk, C. J.; Groettrup, M. Erratum: A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis Nat. Med. 2009, 15 (11) 1333
6. Neubert, K.; Meister, S.; Moser, K.; Weisel, F.; Maseda, D.; Amann, K.; Wiethe, C.; Winkler, T. H.; Kalden, J. R.; Manz, R. A.; Voll, R. E. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis Nat. Med. 2008, 14 (7) 748-755
7. Kincaid, E. Z.; Che, J. W.; York, I.; Escobar, H.; Reyes-Vargas, E.; Delgado, J. C.; Welsh, R. M.; Karow, M. L.; Murphy, A. J.; Valenzuela, D. M.; Yancopoulos, G. D.; Rock, K. L. Mice completely lacking immunoproteasomes show major changes in antigen presentation Nat. Immunol. 2012, 13 (2) 129-135
8. Guillaume, B.; Stroobant, V.; Bousquet-Dubouch, M. P.; Colau, D.; Chapiro, J.; Parmentier, N.; Dalet, A.; Van den Eynde, B. J. Analysis of the processing of seven human tumor antigens by intermediate proteasomes J. Immunol. 2012, 189 (7) 3538-3547
9. Frohlich, K.; Holle, J. U.; Aries, P. M.; Gross, W. L.; Moosig, F. Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma Ann. Rheum. Dis. 2011, 70 (7) 1344-1345
10. Raghavan, R.; Jeroudi, A.; Achkar, K.; Gaber, A. O.; Patel, S. J.; Abdellatif, A. Bortezomib in kidney transplantation J. Transplant. 2010, 2010, 698594
11. Muchamuel, T.; Basler, M.; Aujay, M. A.; Suzuki, E.; Kalim, K. W.; Lauer, C.; Sylvain, C.; Ring, E. R.; Shields, J.; Jiang, J.; Shwonek, P.; Parlati, F.; Demo, S. D.; Bennett, M. K.; Kirk, C. J.; Groettrup, M. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis Nat. Med. 2009, 15 (7) 781-787
12. Ichikawa, H. T.; Conley, T.; Muchamuel, T.; Jiang, J.; Lee, S.; Owen, T.; Barnard, J.; Nevarez, S.; Goldman, B. I.; Kirk, C. J.; Looney, R. J.; Anolik, J. H. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells Arthritis Rheum. 2012, 64 (2) 493-503
13. Kalim, K. W.; Basler, M.; Kirk, C. J.; Groettrup, M. Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation J. Immunol. 2012, 189, 4182-4193
14. Singh, A. V.; Bandi, M.; Aujay, M. A.; Kirk, C. J.; Hark, D. E.; Raje, N.; Chauhan, D.; Anderson, K. C. PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo Br. J. Hamaetol. 2011, 152 (2) 155-163
15. Kisselev, A. F.; van der Linden, W. A.; Overkleeft, H. S. Proteasome inhibitors: an expanding army attacking a unique target Chem. Biol. 2012, 19 (1) 99-115
16. Sharma, L. K.; Lee, N. R.; Jang, E. R.; Lei, B.; Zhan, C. G.; Lee, W.; Kim, K. B. Activity-based near-infrared fluorescent probe for LMP7: a chemical proteomics tool for the immunoproteasome in living cells ChemBioChem 2012, 13 (13) 1899-1903
17. Ho, Y. K.; Bargagna-Mohan, P.; Wehenkel, M.; Mohan, R.; Kim, K. B. LMP2-specific inhibitors: Chemical genetic tools for proteasome biology Chem. Biol. 2007, 14 (4) 419-430
18. Basler, M.; Lauer, C.; Moebius, J.; Weber, R.; Przybylski, M.; Kisselev, A. F.; Tsu, C.; Groettrup, M. Why the structure but not the activity of the immunoproteasome subunit low molecular mass polypeptide 2 rescues antigen presentation J. Immunol. 2012, 189 (4) 1868-1877
19. Kuhn, D. J.; Hunsucker, S. A.; Chen, Q.; Voorhees, P. M.; Orlowski, M.; Orlowski, R. Z. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors Blood 2009, 113 (19) 4667-4676
20. Lin, G.; Tsu, C.; Dick, L.; Zhou, X. K.; Nathan, C. Distinct specificities of Mycobacterium tuberculosis and mammalian proteasomes for N -acetyl tripeptide substrates J. Biol. Chem. 2008, 283 (49) 34423-34431
21. Huber, E. M.; Basler, M.; Schwab, R.; Heinemeyer, W.; Kirk, C. J.; Groettrup, M.; Groll, M. Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity Cell 2012, 148 (4) 727-738
22. Lin, G.; Chidawanyika, T.; Tsu, C.; Warrier, T.; Vaubourgeix, J.; Blackburn, C.; Gigstad, K.; Sintchak, M.; Dick, L.; Nathan, C. N,C-Capped dipeptides with selectivity for mycobacterial proteasome over human proteasomes: role of S3 and S1 binding pockets J. Am. Chem. Soc. 2013, 135 (27) 9968-9971
23. Lin, G.; Li, D.; de Carvalho, L. P.; Deng, H.; Tao, H.; Vogt, G.; Wu, K.; Schneider, J.; Chidawanyika, T.; Warren, J. D.; Li, H.; Nathan, C. Inhibitors selective for mycobacterial versus human proteasomes Nature 2009, 461 (7264) 621-626
24. Blackburn, C.; Gigstad, K. M.; Hales, P.; Garcia, K.; Jones, M.; Bruzzese, F. J.; Barrett, C.; Liu, J. X.; Soucy, T. A.; Sappal, D. S.; Bump, N.; Olhava, E. J.; Fleming, P.; Dick, L. R.; Tsu, C.; Sintchak, M. D.; Blank, J. L. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit Biochem. J. 2010, 430 (3) 461-476